Volunteers needed for diabetic retinopathy study

October 28, 2009

Penn State Milton S. Hershey Medical Center’s Dr. Ingrid U. Scott is investigating whether doxycycline can slow down the deterioration or improve retinal function in people with mild to moderate diabetic retinopathy. Diabetic retinopathy, damage to the eye’s retina that occurs with long-term diabetes, is the leading cause of blindness in working-age Americans.

Individuals with mild to moderate diabetic retinopathy may be eligible to participate in this study. Participation includes a screening visit for eligibility, visits every six months for 24 months, and taking a study medication (either doxycycline or an inactive capsule called a placebo) every day for 24 months.

A complete eye exam along with visual function tests will be performed at each visit.

To be eligible, participants must be 18 years or older, have type 1 or type 2 diabetes with mild to moderate diabetic retinopathy, be able to perform reliable visual function tests, have 20/40 or better vision in the study eye, no history of ocular treatments or laser surgeries for diabetic retinopathy in the study eye, no history of glaucoma and have a stable medical history.

For more information, call study coordinator Mary Hershey at 717-531-6779.

This research study has been approved by the Institutional Review Board, under federal regulations, at the Penn State Milton S. Hershey Medical Center.
 

(Media Contacts)

Last Updated October 29, 2009